Cabergoline vs intravenous albumin or combination of both for prevention of the early onset ovarian hyperstimulation syndrome

Middle East Fertility Society Journal

Volumn 16, Issue 1, 2011, Pages 56-60

  Soliman, Badeea S ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

ART; Cabergoline; I.V Albumin; OHSS; Prevention

Indexed keywords

CABERGOLINE; CHORIONIC GONADOTROPIN; ESTRADIOL; HUMAN ALBUMIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HIGH RISK PATIENT; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LOW DRUG DOSE; MONOTHERAPY; ONSET AGE; OOCYTE RETRIEVAL; OVARY FOLLICLE; OVARY HYPERSTIMULATION;

EID: 79960441071     PISSN: 11105690     EISSN: 20903251     Source Type: Journal    
DOI: 10.1016/j.mefs.2010.10.004     Document Type: Article

References (29)

1. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 2003;9:77-96. (Pubitemid 36305585)
2. Michaelson-Cohen R, Altarescu G, Beller U, Reens R, Halevy- Shalem T, Eldar-Geva T. Does elevated human chorionic gonadotropin alone trigger spontaneous ovarian hyperstimulation syndrome? Fertil Steril 2008;90:1869-74.
3. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Hum Reprod Update 2002;8:559-77. (Pubitemid 35452781)
4. Vlahos NF, Gregoriou O. Prevention and management of ovarian hyperstimulation syndrome. Ann N Y Acad Sci 2006;1092: 247-64. (Pubitemid 47092342)
5. Papanikolaou EG, Tournaye H, Verpoest W, et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod 2005;20:636-41. (Pubitemid 40425488)
6. Vloeberghs V, Peeraer K, Pexsters A, D'Hooghe T. Ovarian hyperstimulation syndrome and complications of ART. Best Pract Res Clin Obstet Gynecol 2009;23:691-709.
7. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001;7:569-74. (Pubitemid 32448324)
8. Álvarez C, Martí-Bonmatí L, Novella-Maestre E, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyper stimulated women undergoing assisted reproduction. J Clin End Metab 2007;92:2931-7.
9. Kapiteijn K, Koolwijk P, van der Wieden RM, van Nieuw Amerongen G, Plaisier M, van Hinsbergh VW, Helmerhorst FM. Human embryo-conditioned medium stimulates in vitro endometrial angiogenesis. Fertil Steril 2006;85:1232-9.
10. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella- Maestre E, Alonso-Muriel I, et al. Low dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-de-cabergoline versus coasting in OHSS dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400-11. (Pubitemid 44790595)
11. Liu C, Tyrrell JB. Successful treatment of a large macro prolactinoma with Cabergoline during pregnancy. Pituitary 2001;4:179-85. (Pubitemid 34679334)
12. Bohnet HG, Muhlenstedt D, Hanker JP, Schneider HP. Prolactin over suppression. Arch Gynakol 1977;223:173-8.
13. Asch R, Ivery G, Goldsman M. The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum Reprod 1993;8:1015-20. (Pubitemid 23204683)
14. Chen CD, Chao KH, Yang JH, et al. Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome. Fertil Steril 2003;80:86-90.
15. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003;9:275-89. (Pubitemid 36827064)
16. Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Tudech Salgueiro P, Tao Jine L, Nagy P, Abdelmassih R. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: A prospective randomized study. Reprod Biomed Online 2008;17:751-5.
17. Griesinger G, von Otte S, Schroer A, et al. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: A prospective, observational proof-of-concept study. Hum Reprod 2007;22:1348-52. (Pubitemid 47062805)
18. Craft I, Hodgson D. Low dose of HCG to prevent OHSS. Reprod Biomed Online 2007;15:354. (Pubitemid 47430377)
19. Griesinger G, Diedrich K, Devroy P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: A systematic review and meta analysis. Hum Reprod Update 2006;12:156-68.
20. Sher G, Salem R, Feinman M, Dodge S, Zouves C, Knutzen V. Eliminating the risk of life-endangering complications following over stimulation with menotropin fertility agents: A report on women undergoing in vitro fertilization and embryo transfer. Obstet Gynecol 1993;81:1009-11. (Pubitemid 23168750)
21. Egbase PE. Severe OHSS: how many cases are preventable? Hum Reprod 2000;15:8-10
22. Zanettini R, Antonini A, Gatto G, et al. Valvular heart diseaseand the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46. (Pubitemid 46041752)
23. Molitch ME. Management of prolactinomas during pregnancy. J Reprod Med 1999;44:1121-6. (Pubitemid 30030170)
24. Manno M, Tomei F, Marchesan E, Adamo V. Cabergoline: A safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Biol 2005;122:127-8.
25. Kumbak B, Kahraman S, Karlikaya G, Karagozoglu H, Sen T, Hatirnaz S. Intravenous albumin prophylaxis in high risk patients for moderate to severe ovarian hyperstimulation syndrome. Istanbul Memorial Hospital, ART Genetic Center 2005;84(1 Suppl):S264.
26. Aboulghar M, Evers JH, Al-Inany H. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: A Cochrane review. Hum Reprod 2002;17:3027-32. (Pubitemid 35469247)
27. Bellver J, Muň oz EA, Ballesteros A, et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: A randomized controlled study. Hum Reprod 2003;18:2283-8. (Pubitemid 37427804)
28. Isikoglu M, Berkkanoglu M, Senturk Z, Ozgur K. Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: A prospective randomized placebo controlled double blind study. Fertil Steril 2007;88:982-5. (Pubitemid 47498350)
29. Prakash A, Karasu T, Mathur R. Ovarian hyperstimulation syndrome: pathophysiology, prevention and management. Obstet Gynecol Reprod Med 2009;19:247-52.